Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 12/20 | 0.72 |
| ▸ | JAK1 | P23458 | 11/20 | 0.72 |
| ▸ | TTK | P33981 | 3/20 | 0.72 |
| ▸ | TYK2 | P29597 | 2/20 | 0.72 |
| ▸ | JAK3 | P52333 | 17/20 | 0.65 |
| ▸ | AURKA | O14965 | 1/20 | 0.59 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15560326 | 0.90 | JAK2 (0.74) | JAK2JAK1TTKTYK2JAK3 | |
| SCHEMBL16782470 | 0.88 | JAK2 (0.70) | JAK2JAK1TTKTYK2JAK3 | |
| SCHEMBL15546548 | 0.87 | JAK2 (0.69) | JAK2JAK1TTKTYK2JAK3 | |
| SCHEMBL19417664 | 0.86 | JAK2 (0.69) | JAK2JAK1TTKTYK2JAK3 | |
| SCHEMBL16782618 | 0.86 | JAK2 (0.69) | JAK2JAK1TTKTYK2JAK3 | |
| SCHEMBL15547431 | 0.86 | JAK1 (0.69) | JAK2JAK1TTKTYK2JAK3 | |
| SCHEMBL15547919 | 0.86 | JAK2 (0.69) | JAK2JAK1TTKTYK2JAK3 | |
| SCHEMBL16782568 | 0.86 | JAK1 (0.68) | JAK2JAK1TTKTYK2JAK3 | |
| SCHEMBL16782458 | 0.86 | JAK2 (0.67) | JAK2JAK1TTKTYK2JAK3 | |
| SCHEMBL15546922 | 0.85 | JAK2 (0.77) | JAK2JAK1TTKTYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11789025-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-10969394-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20210072254-A1 | Reagents and Methods for Analysis of Proteins and Metabolites Targeted by Covalent Probes | DANA-FARBER CANCER INSTITUTE, INC. | 2021-03-11 | — | — | US | disclosed |
| US-20190346454-A1 | Reagents and Methods for Analysis of Proteins and Metabolites Targeted by Covalent Probes | DANA-FARBER CANCER INSTITUTE, INC. | 2019-11-14 | — | — | US | disclosed |
| WO-2018098473-A1 | REAGENTS AND METHODS FOR ANALYSIS OF PROTEINS AND METABOLITES TARGETED BY COVALENT PROBES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10969394-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | PTMS, SRMS, HSP90B1 | JAK2 4046/4885JAK1 4784/4885TTK 2638/4885 |
| US-11789025-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | PTMS, SRMS, HSP90B1 | JAK2 4046/4885JAK1 4784/4885TTK 2638/4885 |
| US-20210072254-A1 | Reagents and Methods for Analysis of Proteins and Metabolites Targeted by Covalent Probes | PTMS, SRMS, HSP90B1 | JAK2 4046/4885JAK1 4784/4885TTK 2638/4885 |
| US-20190346454-A1 | Reagents and Methods for Analysis of Proteins and Metabolites Targeted by Covalent Probes | PTMS, SRMS, HSP90B1 | JAK2 4046/4885JAK1 4784/4885TTK 2638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.